›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Oncomine™ Comprehensive Assay Plus
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Thermo Fisher ScientificType:
Laboratory Developed Test
Related tests:
The Oncomine Comprehensive Assay Plus is part of Oncomine™ Solutions, a broad assay menu for all key oncology applications. It covers over 500 unique genes, including key cancer driver genes such as EGFR, BRAF, KRAS, ERBB2, and MET, fusions involving ALK, ROS1, RET, and NTRK1/2/3, and more. It enables pan-cancer genomic profiling across multiple biomarkers with high testing success.
Cancer:
Colon Cancer, Thyroid Gland Carcinoma
Gene:
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2)
See More ...
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
Method:
Next-Generation Sequencing (NGS)
